Abstract
A large number of the new pharmaceutical small molecules under development today are found to have poor water solubility. This in turn may lead to low bioavailability, which can have a significant impact on the development of the compound. Compounds with low bioavailability pose a greater challenge in early preclinical work involving animal studies, where obtaining maximum exposure is the primary goal especially in toxicology studies designed to establish the safe dose. From the standpoint of maximizing exposure, the amorphous phase is of great interest as pharmaceutical materials since it is the most metastable state and as such offers the potential of higher solubility and better bioavailability. However, the amorphous approach is not actively pursued in preclinical work owing to the tendency of the amorphous phase to crystallize thereby neutralizing the solubility advantage. This review focuses on (i) methods to generate the amorphous phase, (ii) methods to estimate the degree of crystallinity of the amorphous phase, (iii) methods to predict the stability of the amorphous phase against crystallization, and (iv) choice of polymers carrier and formulation of the amorphous phase for preclinical studies.
Keywords: Amorphous pharmaceuticals, crystallization, preclinical, solid dispersions
Current Bioactive Compounds
Title: Amorphous Active Pharmaceutical Ingredients in Preclinical Studies: Preparation, Characterization, and Formulation
Volume: 4 Issue: 4
Author(s): Karthik Nagapudi and Janan Jona
Affiliation:
Keywords: Amorphous pharmaceuticals, crystallization, preclinical, solid dispersions
Abstract: A large number of the new pharmaceutical small molecules under development today are found to have poor water solubility. This in turn may lead to low bioavailability, which can have a significant impact on the development of the compound. Compounds with low bioavailability pose a greater challenge in early preclinical work involving animal studies, where obtaining maximum exposure is the primary goal especially in toxicology studies designed to establish the safe dose. From the standpoint of maximizing exposure, the amorphous phase is of great interest as pharmaceutical materials since it is the most metastable state and as such offers the potential of higher solubility and better bioavailability. However, the amorphous approach is not actively pursued in preclinical work owing to the tendency of the amorphous phase to crystallize thereby neutralizing the solubility advantage. This review focuses on (i) methods to generate the amorphous phase, (ii) methods to estimate the degree of crystallinity of the amorphous phase, (iii) methods to predict the stability of the amorphous phase against crystallization, and (iv) choice of polymers carrier and formulation of the amorphous phase for preclinical studies.
Export Options
About this article
Cite this article as:
Nagapudi Karthik and Jona Janan, Amorphous Active Pharmaceutical Ingredients in Preclinical Studies: Preparation, Characterization, and Formulation, Current Bioactive Compounds 2008; 4 (4) . https://dx.doi.org/10.2174/157340708786847852
DOI https://dx.doi.org/10.2174/157340708786847852 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease
Current Drug Targets Protein Conformational Pathology in Alzheimers and Other Neurodegenerative Diseases; New Targets for Therapy
Current Alzheimer Research Overview of Coumarins and its Derivatives: Synthesis and Biological Activity
Letters in Organic Chemistry Treatment Approaches in Elderly Patients with Head and Neck Cancer
Anti-Cancer Agents in Medicinal Chemistry Defining Primary and Secondary Progenitor Disorders in the Brain: Proteomic Approaches for Analysis of Neural Progenitor Cells
Current Pharmaceutical Biotechnology Perspectives on Developing Small Molecule Inhibitors Targeting HIV-1 Integrase
Mini-Reviews in Medicinal Chemistry May Patients with Alcohol Liver Disease Benefit from Herbal Medicines?
Reviews on Recent Clinical Trials Exploring the Evidence Implicating the Renin-Angiotensin System (RAS) in the Physiopathology of Mood Disorders
Protein & Peptide Letters Efficacy of Pharmacotherapy for Comorbid Major Depression and Substance Use Disorders: A review
Current Psychiatry Reviews Humanin Nanoparticles for Reducing Pathological Factors Characteristic of Age-Related Macular Degeneration
Current Drug Delivery CD31+ Circulating Angiogenic Cell Number and Subtypes are Reduced in Individuals with Chronic Stroke
Current Neurovascular Research Fenofibrate Increases Heme Oxygenase 1 Expression and Astrocyte Proliferation While Limits Neuronal Injury During Intracerebral Hemorrhage
Current Neurovascular Research Direct Analysis of Methadone in Exhaled Breath Condensate by Capillary Zone Electrophoresis
Current Pharmaceutical Analysis Meet Our Editorial Board Members:
Current Genomics Impacts of Pseudo Amino Acid Components and 5-steps Rule to Proteomics and Proteome Analysis
Current Topics in Medicinal Chemistry Lack of Association between Genetic Polymorphism of Circadian Genes (PER2, PER3, CLOCK and OX2R) with Late Onset Depression and Alzheimer's Disease in a Sample of a Brazilian Population (Circadian Genes, Late-Onset Depression and Alzheimer's Disease)
Current Alzheimer Research Phosphodiesterase 4 Inhibitors for the Treatment of Asthma and COPD
Current Medicinal Chemistry Multiple Non-Equivalent Interfaces Mediate Direct Activation of GABAA Receptors by Propofol
Current Neuropharmacology Prolyl Oligopeptidase Structure and Dynamics
CNS & Neurological Disorders - Drug Targets Targeting Leukocytes in Immune Glomerular Diseases
Current Medicinal Chemistry